Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

I believe that Repatha, Blincyto, Tepezza, Krystexxa, and Tezspire are the medications that will continue to have a significant impact on improving Amgen's financial position in the long term.

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.

Amgen is a leader in biotechnology-based human ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon ...

Repatha (reducing cholesterol), Aimovig (migraine ... indications (such as chronic obstructive pulmonary disease). Amgen Inc. (NASDAQ:AMGN) increased its projection for FY 2024 operating EPS ...